Bradley Stohr, MD, PhD

Title(s)Associate Professor, Pathology
SchoolSchool of Medicine
Address513 Parnassus Avenue, HSW, #450E
San Francisco CA 94143
Phone415-476-6729
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoClinical Fellowship

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    The Response of Cancer and Stem/Progenitor Cells to Telomere Disruption
    NIH K08CA134552Jul 15, 2009 - Jun 30, 2014
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells. Hum Pathol. 2023 Mar 29; 136:56-62. Bahceci D, Nguyen JK, Sangoi AR, Stohr BA, Chan E. PMID: 36997033.
      View in: PubMed   Mentions:    Fields:    
    2. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Res. 2023 01 18; 83(2):301-315. Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. PMID: 36351060.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    3. Molecular characterization of adenocarcinomas arising in the urinary bladder following augmentation cystoplasty: a multi-institutional study. Hum Pathol. 2022 11; 129:98-102. Stohr BA, Chan E, Anderson JA, Matoso A, Murati Amador BI, Cheng L, Osunkoya AO. PMID: 36108931.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. PD11-12 ASSOCIATIONS OF SERUM-BASED AND URINE-BASED MOLECULAR DIAGNOSTICS WITH HISTOLOGIC SUBTYPING ON PROSTATE BIOPSY. Investigative Urology. 2022 May 1; 207(Supplement 5):e194. de la Calle dC, Greenland GN, Cowan CJ, Fasulo FV, Maggi MM, Chan CE, Stohr SB, Simko SJ, Shinohara SK, Cooperberg CM, Carroll CP, Nguyen NH. .
      View in: Publisher Site   Mentions:
    5. p53 null phenotype is a "positive result" in urothelial carcinoma in situ. Mod Pathol. 2022 09; 35(9):1287-1292. Sangoi AR, Chan E, Abdulfatah E, Stohr BA, Nguyen J, Trpkov K, Siadat F, Hirsch M, Falzarano S, Udager AM, Kunju LP. PMID: 35322193.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma. Pathol Res Pract. 2022 Apr; 232:153831. Peng Y, Greenland NY, Lang UE, Stohr BA. PMID: 35287088.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    7. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. PMID: 35321431; PMCID: PMC8935010.
      View in: PubMed   Mentions: 3  
    8. Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease. Am J Surg Pathol. 2022 03 01; 46(3):392-403. Chan E, Stohr BA, Butler RS, Cox RM, Myles JL, Nguyen JK, Przybycin CG, Reynolds JP, Williamson SR, McKenney JK. PMID: 34881751.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022 12; 5(6):714-718. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. PMID: 35216942.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    10. Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC). Journal of Clinical Oncology. 2022 Feb 20; 40(6_suppl):531-531. Jindal JT, Zhang ZL, Chou CJ, Shui SD, Porten PS, Wong WA, Chan CE, Stohr SB, de Kouchkovsky dI, Borno BH, Bose BR, Kwon KD, Desai DA, Huang HF, Aggarwal AR, Small SE, Fong FL, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    11. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun. 2022 01 10; 13(1):141. Song H, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang H, Castro EA, Lu KL, Stohr BA, Feng FY, Carroll PR, Wang B, Cooperberg MR, Shalek AK, Huang FW. PMID: 35013146; PMCID: PMC8748675.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    12. Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. Investig Clin Urol. 2022 01; 63(1):27-33. Greenland NY, Cooperberg MR, Wong AC, Chan E, Carroll PR, Simko JP, Stohr BA. PMID: 34983120; PMCID: PMC8756156.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis. Hum Pathol. 2022 01; 119:85-93. Chen CV, Croom NA, Simko JP, Stohr BA, Chan E. PMID: 34800526.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. MP66-08 SINGLE-CELL TRANSCRIPTIONAL PROFILES OF HISTOLOGIC VARIANTS IN BLADDER CANCER. Investigative Urology. 2021 Sep 1; 206(Supplement 3). Yang YH, Song SH, Allegakoen AP, Xie XJ, Lu LK, Stohr SB, Meng MM, Porten PS, Huang HF. .
      View in: Publisher Site   Mentions:
    15. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 09 15; 27(18):5123-5130. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. PMID: 34108177; PMCID: PMC8634828.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    16. Metabolic imaging with hyperpolarized 13 C pyruvate magnetic resonance imaging in patients with renal tumors-Initial experience. Cancer. 2021 08 01; 127(15):2693-2704. Tang S, Meng MV, Slater JB, Gordon JW, Vigneron DB, Stohr BA, Larson PEZ, Wang ZJ. PMID: 33844280; PMCID: PMC8565774.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    17. Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):463-463. Chu CC, Sjöström SM, Egusa EE, Gibb GE, Badura BM, Koshkin KV, Stohr SB, Meng MM, Pruthi PR, Friedlander FT, Lotan LY, Black BP, Porten PS, Feng FF, Chou CJ. .
      View in: Publisher Site   Mentions:
    18. Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category. Prostate. 2020 12; 80(16):1421-1428. Greenland NY, Cowan JE, Chan E, Carroll PR, Stohr BA, Simko JP. PMID: 32946625.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study. Pathology. 2021 Feb; 53(2):214-219. Anderson JA, Matoso A, Murati Amador BI, Cheng L, Stohr BA, Chan E, Osunkoya AO. PMID: 32951908; PMCID: PMC9281534.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma. Annals of Oncology. 2020 Sep 1; 31:s593. Natesan ND, Zhang ZL, Martell MH, Devine DP, Stohr SB, Grenert GJ, Van Ziffle VJ, Joseph JN, Bastian BB, Umetsu US, Onodera OC, Chan CE, Desai DA, Porten PS, Chou CJ, Friedlander FT, Fong FL, Small SE, Sweet-Cordero SA, Koshkin KV. .
      View in: Publisher Site   Mentions:
    21. Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin. Hum Pathol. 2020 08; 102:54-59. Sangoi AR, Chan E, Stohr BA, Kunju LP. PMID: 32673685.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    22. Correlation of tumor mutational burden (TMB) with molecular profiling and clinical characteristics in patients with bladder cancer. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e17025-e17025. Natesan ND, Martell MH, Devine DP, Stohr SB, Grenert GJ, Van Ziffle VJ, Joseph JN, Bastian BB, Umetsu US, Onodera OC, Chan CE, Desai DA, Wong WA, Porten PS, Chou CJ, Friedlander FT, Small SE, Fong FL, Sweet-Cordero SE, Koshkin KV. .
      View in: Publisher Site   Mentions:
    23. Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma. Pract Lab Med. 2020 Aug; 21:e00164. Lei L, Stohr BA, Berry S, Lockwood CM, Davis JL, Rudzinski ER, Kunder CA. PMID: 32490123; PMCID: PMC7260589.
      View in: PubMed   Mentions: 1  
    24. Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution. Histopathology. 2020 Jun; 76(7):1084-1090. Chan E, Stohr BA, Croom NA, Cho SJ, Garg K, Troxell ML, Higgins JP, Bean GR. PMID: 32064677.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. Am J Surg Pathol. 2020 05; 44(5):571-581. Shah RB, Stohr BA, Tu ZJ, Gao Y, Przybycin CG, Nguyen J, Cox RM, Rashid-Kolvear F, Weindel MD, Farkas DH, Trpkov K, McKenney JK. PMID: 31850909.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    26. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer. Mod Pathol. 2020 09; 33(9):1802-1810. Chan E, Garg K, Stohr BA. PMID: 32313185.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4. Prostate. 2020 05; 80(8):653-659. Greenland NY, Cowan JE, Zhang L, Carroll PR, Chan E, Stohr BA, Simko JP. PMID: 32220141.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    28. Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration. Cell Stem Cell. 2020 01 02; 26(1):27-33.e4. Chen F, Jimenez RJ, Sharma K, Luu HY, Hsu BY, Ravindranathan A, Stohr BA, Willenbring H. PMID: 31866223; PMCID: PMC8009755.
      View in: PubMed   Mentions: 51     Fields:    Translation:Cells
    29. In Situ Visualization of Telomere Length, Telomere Elongation, and TERT Expression in Single Cells. Curr Protoc Cell Biol. 2019 12; 85(1):e97. Ravindranathan A, Diolaiti ME, Cimini BA, Stohr BA. PMID: 31763768.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    30. Pathophysiology, Clinical Manifestations, and Treatment of Lichen Sclerosus: A Systematic Review. Urology. 2020 Jan; 135:11-19. Fergus KB, Lee AW, Baradaran N, Cohen AJ, Stohr BA, Erickson BA, Mmonu NA, Breyer BN. PMID: 31605681.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    31. TP53 structural variants in metastatic prostatic carcinoma. PLoS One. 2019; 14(6):e0218618. Sirohi D, Devine P, Grenert JP, van Ziffle J, Simko JP, Stohr BA. PMID: 31216325; PMCID: PMC6583940.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    32. Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. J Urol. 2019 07; 202(1):90-95. Greenland NY, Zhang L, Cowan JE, Carroll PR, Stohr BA, Simko JP. PMID: 30810466.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    33. Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. Am J Surg Pathol. 2019 04; 43(4):435-445. Davis JL, Lockwood CM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette M, Turpin B, Szabo S, Laetsch TW, Albert CM, Parham DM, Hawkins DS, Rudzinski ER. PMID: 30585824.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    34. Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance. Journal of Clinical Oncology. 2019 Mar 1; 37(7_suppl):88-88. Zuniga ZK, Washington WS, Simko SJ, Greenland GN, Stohr SB, Cowan CJ, Tenggara TI, Maggi MM, Chan CJ, Cooperberg CM, Carroll CP. .
      View in: Publisher Site   Mentions:
    35. Preliminary development of an assay for detection of TERT expression, telomere length, and telomere elongation in single cells. PLoS One. 2018; 13(12):e0206525. Ravindranathan A, Cimini B, Diolaiti ME, Stohr BA. PMID: 30517099; PMCID: PMC6281304.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    36. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. Eur Urol. 2018 11; 74(5):668-675. Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR. PMID: 30181067.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    37. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. Am J Surg Pathol. 2018 07; 42(7):927-935. Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW, Davis JL. PMID: 29683818.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    38. Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study. Mod Pathol. 2018 09; 31(9):1429-1441. Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, Federman S, Vankalakunti M, Koo J, Bose S, Peralta-Venturina M, Ziffle JV, Grenert JP, Miller S, Chiu C, Amin MB, Simko JP, Stohr BA, Luthringer DJ. PMID: 29765141.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    39. Next-Generation Sequencing Assay Raises New Questions in a Case of Metastatic Prostate Cancer. J Appl Lab Med. 2018 May 01; 2(6):960-964. Abadie JM, Stohr BA. PMID: 33636819.
      View in: PubMed   Mentions:    Fields:    
    40. PD56-12 COMPARISON OF A LOW-COST IMMUNOHISTOCHEMISTRY MARKER PANEL WITH A CELL-CYCLE PROGRESSION ASSAY FOR THE PREDICTION OF OUTCOME AFTER RADICAL PROSTATECTOMY. The Journal of Urology. 2018 Apr 1; 199(4):e1066. Leapman LM, Nguyen NH, Cowan CJ, Xue XL, Stohr SB, Simko SJ, Cooperberg CM, Carroll CP. .
      View in: Publisher Site   Mentions:
    41. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal of Clinical Oncology. 2018 Feb 20; 36(6_suppl):118-118. Leapman LM, Nguyen NH, Cowan CJ, Xue XL, Stohr SB, Simko SJ, Cooperberg CM, Carroll CP. .
      View in: Publisher Site   Mentions:
    42. Reply to Chou et al 'Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution' Mod Pathol 2017; in press. Mod Pathol. 2017 10; 30(10):1509-1511. Williamson SR, Grignon DJ, Calió A, Stohr BA, Eble JN, Cheng L. PMID: 28972584.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    43. Targeted next-generation DNA sequencing of paired tumor and normal DNA to reveal frequent actionable germline alterations. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):11575-11575. Korn KW, Yey YI, Van Ziffle VJ, Grenert GJ, Joseph JN, Solomon SD, Laurance LM, Talevich TE, Onodera OC, Krings KG, Stohr SB, Blanco BA, Bastian BB. .
      View in: Publisher Site   Mentions:
    44. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. Eur Urol. 2017 05; 71(5):750-759. Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. PMID: 27940155.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    45. Renal cell carcinoma with TFE3 translocation and succinate dehydrogenase B mutation. Mod Pathol. 2017 03; 30(3):407-415. Calió A, Grignon DJ, Stohr BA, Williamson SR, Eble JN, Cheng L. PMID: 27910947.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    46. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol. 2016 09; 29(9):1012-27. Liu SY, Joseph NM, Ravindranathan A, Stohr BA, Greenland NY, Vohra P, Hosfield E, Yeh I, Talevich E, Onodera C, Van Ziffle JA, Grenert JP, Bastian BC, Chen YY, Krings G. PMID: 27255162.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    47. Nuclear size is sensitive to NTF2 protein levels in a manner dependent on Ran binding. J Cell Sci. 2016 Mar 15; 129(6):1115-27. Vukovic LD, Jevtic P, Zhang Z, Stohr BA, Levy DL. PMID: 26823604; PMCID: PMC4813295.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    48. Functional Analysis of the Bacteriophage T4 Rad50 Homolog (gp46) Coiled-coil Domain. J Biol Chem. 2015 Sep 25; 290(39):23905-15. Barfoot T, Herdendorf TJ, Behning BR, Stohr BA, Gao Y, Kreuzer KN, Nelson SW. PMID: 26242734; PMCID: PMC4583041.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    49. The Shelterin TIN2 Subunit Mediates Recruitment of Telomerase to Telomeres. PLoS Genet. 2015 Jul; 11(7):e1005410. Frank AK, Tran DC, Qu RW, Stohr BA, Segal DJ, Xu L. PMID: 26230315; PMCID: PMC4521702.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    50. Autophagy-independent senescence and genome instability driven by targeted telomere dysfunction. Autophagy. 2015; 11(3):527-37. Mar FA, Debnath J, Stohr BA. PMID: 25751002; PMCID: PMC4502814.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    51. Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. Nature. 2014 Aug 14; 512(7513):198-202. Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, Alvarez S, Diolaiti ME, Ugarte F, Forsberg EC, Le Beau MM, Stohr BA, Méndez J, Morrison CG, Passegué E. PMID: 25079315; PMCID: PMC4456040.
      View in: PubMed   Mentions: 301     Fields:    Translation:AnimalsCells
    52. FPA144, a humanized monoclonal antibody for both FGFR2 -amplified and nonamplified, FGFR2b -overexpressing gastric cancer patients. Journal of Clinical Oncology. 2014 May 20; 32(15_suppl):e15074-e15074. Pierce PK, Deshpande DA, Stohr SB, Gemo GA, Patil PN, Brennan BT, Bellovin BD, Palencia PS, Giese GT, Huang HC, Baker BK, Kavanaugh KW, Hambleton HJ, Los LG. .
      View in: Publisher Site   Mentions:
    53. Coordination and processing of DNA ends during double-strand break repair: the role of the bacteriophage T4 Mre11/Rad50 (MR) complex. Genetics. 2013 Nov; 195(3):739-55. Almond JR, Stohr BA, Panigrahi AK, Albrecht DW, Nelson SW, Kreuzer KN. PMID: 23979587; PMCID: PMC3813861.
      View in: PubMed   Mentions: 5     Fields:    Translation:Cells
    54. In situ visualization of telomere elongation patterns in human cells. Nucleic Acids Res. 2013 Oct; 41(18):e176. Diolaiti ME, Cimini BA, Kageyama R, Charles FA, Stohr BA. PMID: 23963699; PMCID: PMC3794614.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    55. The role of telomere biology in cancer. Annu Rev Pathol. 2013 Jan 24; 8:49-78. Xu L, Li S, Stohr BA. PMID: 22934675.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimalsCells
    56. A novel sarcoma with dual differentiation: clinicopathologic and molecular characterization of a combined synovial sarcoma and extraskeletal myxoid chondrosarcoma. Am J Surg Pathol. 2012 Jul; 36(7):1093-8. Vergara-Lluri ME, Stohr BA, Puligandla B, Brenholz P, Horvai AE. PMID: 22743288.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    57. The terminal telomeric DNA sequence determines the mechanism of dysfunctional telomere fusion. Mol Cell. 2010 Jul 30; 39(2):307-14. Stohr BA, Xu L, Blackburn EH. PMID: 20670897; PMCID: PMC2920734.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    58. ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells. Cancer Res. 2008 Jul 01; 68(13):5309-17. Stohr BA, Blackburn EH. PMID: 18593932; PMCID: PMC2553270.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    59. The tight linkage between DNA replication and double-strand break repair in bacteriophage T4. Proc Natl Acad Sci U S A. 2001 Jul 17; 98(15):8290-7. George JW, Stohr BA, Tomso DJ, Kreuzer KN. PMID: 11459966; PMCID: PMC37434.
      View in: PubMed   Mentions: 16     Fields:    Translation:Cells
    60. Repair of topoisomerase-mediated DNA damage in bacteriophage T4. Genetics. 2001 May; 158(1):19-28. Stohr BA, Kreuzer KN. PMID: 11333215; PMCID: PMC1461630.
      View in: PubMed   Mentions: 13     Fields:    Translation:Cells
    With one click, see people who:

    Mentor Faculty

    Offer Student Projects

    Run Clinical Trials

    Work in Global Health Equity

    See more options in the Advanced Search tab

    Bradley's Networks
    Concepts (265)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (60)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version pre_new_search-4-g7119b7be on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.